Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Neutralization of SARS-CoV-2 Omicron BQ.1, BQ.1.1 and XBB.1 variants following SARS-CoV-2 infection or vaccination in children ; volume:14 ; number:1 ; day:1 ; month:12 ; year:2023 ; pages:1-13 ; date:12.2023
Nature Communications ; 14, Heft 1 (1.12.2023), 1-13, 12.2023
- Creator
-
Bellusci, Lorenza
Grubbs, Gabrielle
Sait, Shaimaa
Yonker, Lael M.
Randolph, Adrienne G.
Novak, Tanya
Kobayashi, Takuma
Khurana, Surender
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-023-43152-y
- URN
-
urn:nbn:de:101:1-2024022110203180639457
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Bellusci, Lorenza
- Grubbs, Gabrielle
- Sait, Shaimaa
- Yonker, Lael M.
- Randolph, Adrienne G.
- Novak, Tanya
- Kobayashi, Takuma
- Khurana, Surender
- SpringerLink (Online service)
Other Objects (12)
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Modeling transmission of SARS-CoV-2 Omicron in China
Protein Nanoparticles for Targeted SARS‐CoV‐2 Trapping and Neutralization
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Modeling transmission of SARS-CoV-2 Omicron in China
Protein Nanoparticles for Targeted SARS‐CoV‐2 Trapping and Neutralization
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry
A bispecific antibody exhibits broad neutralization against SARS-CoV-2 Omicron variants XBB.1.16, BQ.1.1 and sarbecoviruses
Neutralization assay with SARS-CoV-1 and SARS-CoV-2 spike pseudotyped murine leukemia virions
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Reduced neutralization of SARS-CoV-2 Omicron variant by vaccine sera and monoclonal antibodies
Heterologous mRNA vaccine booster increases neutralization of SARS-CoV-2 Omicron BA.2 variant
Augmented neutralization of SARS‐CoV‐2 Omicron variant by boost vaccination and monoclonal antibodies
An updated RBD-Fc fusion vaccine booster increases neutralization of SARS-CoV-2 Omicron variants
Antigenic characterization of SARS-CoV-2 Omicron subvariant BA.4.6
Heterotypic vaccination responses against SARS-CoV-2 Omicron BA.2
Modeling transmission of SARS-CoV-2 Omicron in China
Protein Nanoparticles for Targeted SARS‐CoV‐2 Trapping and Neutralization
Antibody neutralization of SARS-CoV-2 through ACE2 receptor mimicry